Hip fracture surgery is unplanned, urgent and unforgiving, and obesity makes it harder. So a study reporting that obese patients on these drugs did better than everyone — including normal-weight patients — is worth reading closely [1]. The fracture evidence itself is in hip fractures halved, which is two people in a thousand.
Overall complications came in at 22.41% for obese patients on at least six months of GLP-1 therapy — 22.41% vs 55.17% — against normal-weight controls, 51.72% in overweight controls and 60.34% in obese non-users. Minor complications followed the same pattern, and the obese non-user group had significantly higher 30-day and 90-day readmissions.
The nulls quietly undercut the headline. Major complications did not differ. Hardware failure did not differ. Thirty-day and one-year outcomes did not differ. What moved was minor complications and readmissions — the softer, more discretionary end of the outcome list, which is also the end most sensitive to how robust a patient looks to the team deciding whether to send them home.
The scale sets the ceiling on all of it. Fifty-eight patients per group at one institution means each individual moves a percentage by 1.7 points, and the authors grade their own evidence as Level III. The same shape — uniform advantage across outcomes, in a group defined by being on maintenance therapy — appears in the spinal fusion cost analysis and in the procedure literature generally.
None of this argues against being on one of these drugs before an accident, and there is nothing here suggesting harm. It argues against reading a claims or chart comparison as evidence that a prescription protects you in an emergency. What these drugs demonstrably do in planned procedures, where holding and preparation are possible, is covered in the pre-procedure hold study and the cervical spine cohort.